ProQR Therapeutics N.V. PRQR

$ 2.52 -4.18%

Annual report 2023
added 12-21-2024

ProQR Therapeutics N.V. Balance Sheet 2011-2024 | PRQR

Annual Balance Sheet ProQR Therapeutics N.V.

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-171 M	-58.4 M	-98.7 M	-96.2 M	-40.9 M	-53.5 M	-90 M	-110 M	-589 K	-153 K	-
Long Term Debt	-	-	14.7 M	16.2 M	12.7 M	9.39 M	5.28 M	5.7 M	4.82 M	2.81 M	943 K	96 K	-
Long Term Debt Current	1.61 M	1.39 M	1.53 M	1.26 M	508 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	31.9 M	12.7 M	9.39 M	5.28 M	5.7 M	4.82 M	2.83 M	991 K	96 K	-
Total Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	96.5 M	106 M	96.4 M	42.2 M	23.7 M	17.5 M	13.8 M	12.4 M	10.3 M	5.84 M	4.59 M	239 K	-
Deferred Revenue	-	-	-	700 K	711 K	545 K	347 K	-	144 K	-	-	-	-
Retained Earnings	-	-	-	-258 M	-212 M	-155 M	-119 M	-75.7 M	-36.6 M	-15.8 M	-3.67 M	-418 K	-
Total Assets	138 M	171 M	210 M	98.7 M	118 M	110 M	53.1 M	65.5 M	100 M	115 M	4.5 M	338 K	-
Cash and Cash Equivalents	119 M	94.8 M	188 M	75.8 M	112 M	106 M	48.1 M	59.2 M	94.9 M	-	-	-	-
Book Value	41.4 M	65.1 M	113 M	56.5 M	93.8 M	92.7 M	39.3 M	53.1 M	89.8 M	109 M	-89 K	99 K	-
Total Shareholders Equity	-	-	113 M	56.5 M	93.8 M	92.7 M	39.3 M	53.1 M	89.8 M	-	-	-	-

All numbers in EUR currency

Quarterly Balance Sheet ProQR Therapeutics N.V.

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	14.4 M	14.7 M	15.1 M	15.5 M	-	15.7 M	14.7 M	-	-	-	-	609 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	68.8 M	-	-	-	31.9 M	-	-	-	12.7 M	-	-	-	9.39 M	-	-	-	5.28 M	-	-	-	5.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	90 M	96.4 M	67.3 M	44.8 M	-	42.2 M	42.1 M	13.9 M	22.3 M	23.7 M	21.6 M	20 M	-	17.5 M	-	14.8 M	-	13.8 M	-	-	-	12.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-	-318 M	-	-	-	-258 M	-	-	-	-212 M	-	-	-	-155 M	-	-	-	-119 M	-	-	-	-75.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	190 M	210 M	195 M	162 M	-	98.7 M	110 M	93.5 M	104 M	118 M	81.1 M	90.3 M	-	110 M	-	37.5 M	-	53.1 M	-	-	-	65.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	168 M	188 M	156 M	139 M	67.9 M	75.8 M	88.8 M	87.1 M	98.1 M	112 M	74.8 M	82.5 M	94.1 M	106 M	114 M	33 M	38 M	48.1 M	-	42.3 M	52.1 M	59.2 M	-	-	-	94.9 M	-	-	-	113 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	100 M	113 M	128 M	118 M	-	56.5 M	68.1 M	79.6 M	81.4 M	93.8 M	59.4 M	70.2 M	-	92.7 M	-	22.7 M	-	39.3 M	-	-	-	53.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	100 M	113 M	128 M	118 M	49.2 M	56.5 M	68.1 M	79.6 M	81.4 M	93.8 M	59.4 M	70.2 M	80.8 M	92.7 M	102 M	22.7 M	-	39.3 M	-	36.8 M	-	53.1 M	-	-	-	89.8 M	-	-	-	109 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency